|Positive WB detected in||K-562 cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Sample-dependent, check data in validation data gallery|
66236-1-Ig targets SALL4 in WB, IHC,ELISA applications and shows reactivity with human samples.
|Host / Isotype||Mouse / IgG1|
|Immunogen||SALL4 fusion protein Ag17480|
|Full Name||sal-like 4 (Drosophila)|
|Calculated molecular weight||1053 aa, 112 kDa|
|Observed molecular weight||165 kDa|
|GenBank accession number||BC111714|
|Gene ID (NCBI)||57167|
|Purification Method||Protein G purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
SALL4, also named as Sal-like protein 4 or Zinc finger protein 797, Contains 7 C2H2-type zinc fingers and belongs to the sal C2H2-type zinc-finger protein family. SALL4 is constitutively expressed in acute myeloid leukemia. The constitutive expression of SALL4in mice is sufficient to induce MDS-like symptoms and transformation to AML that is transplantable. SALL4 is able to bind beta-catenin and activate the Wnt/beta-catenin signaling pathway. Sequence analysis of the larger cDNA fragment isolated revealed a single, large open-reading frame, designated as SALL4A, that started from a strong consensus initiation sequence and was expected to encode 1053 amino acids. The other splicing variant of SALL4, designated SALL4B, lacked the region corresponding to amino acids 385 to 820 of the full-length SALL4A. The putative protein encoded by SALL4B cDNA was expected to consist of 617 amino acids.
Cancer Chemother Pharmacol
Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma.
Pediatr Surg Int
SALL4 is a useful marker for pediatric yolk sac tumors.